Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jul 15, 2026
Aehr Test Systems (AEHR) Delivers Record Bookings and Returns to GAAP Profitability in Fiscal 2026 Q4

Aehr Test Systems (AEHR) Delivers Record Bookings and Returns to GAAP Profitability in Fiscal 2026 Q4

Key Takeaways

  • Aehr Test Systems reported fiscal 2026 fourth-quarter revenue of $18.8 million, up from $14.1 million in the prior-year period.
  • GAAP net income reached $1.4 million, or $0.04 per diluted share, compared to a net loss of $2.9 million, or $0.10 per diluted share, a year earlier.
  • Non-GAAP net income was $3.6 million, or $0.11 per diluted share.
  • Quarterly bookings hit a record $60.7 million, reflecting robust demand for wafer-level and package-level burn-in systems.
  • The company highlighted strong AI and data center infrastructure demand as a key driver of results.
  • Full-year fiscal 2026 revenue guidance was reaffirmed on the high end of the previously stated range.

Earnings Context and Why It Matters

Aehr Test Systems specializes in test and burn-in solutions for semiconductors, with particular exposure to silicon carbide and advanced packaging for AI processors. The fiscal 2026 fourth quarter marked the end of the company’s fiscal year on May 29, 2026. Investors closely monitor these results because Aehr’s revenue can fluctuate with large system orders from hyperscale customers. Recent quarters showed volatility tied to customer order timing, making the latest report a key indicator of demand trends in the AI infrastructure supply chain and the company’s path toward sustained profitability. To get a quick sense of how AEHR compares within the broader semiconductor equipment group, I ran a scan using Tickeron’s AI Screener.

Reported Results

Aehr Test Systems delivered fiscal 2026 fourth-quarter revenue of $18.8 million, an increase from $14.1 million in the same quarter of fiscal 2025. GAAP net income totaled $1.4 million, or $0.04 per diluted share, reversing a prior-year GAAP net loss of $2.9 million, or $0.10 per diluted share. Non-GAAP net income, which excludes stock-based compensation and other items, reached $3.6 million, or $0.11 per diluted share. Quarterly bookings set a new record at $60.7 million. The company also provided updates on its full-year performance and noted that fiscal 2026 revenue is expected to land on the high side of the previously guided $45 million to $50 million range.

Market Reaction and Investor Sentiment

Shares of AEHR moved higher following the July 14, 2026, earnings release, driven by the record bookings figure and the return to GAAP profitability. Investors focused on the strong book-to-bill ratio and visibility into future revenue from AI-related demand. Sentiment heading into the report had been cautious amid prior-quarter variability, but the positive surprise on bookings helped shift focus toward growth prospects in the semiconductor test equipment sector.

Forward Outlook and Key Factors to Monitor

Investors will watch how Aehr converts its elevated backlog into recognized revenue over the coming quarters. The company expects fiscal 2026 second-half revenue between $25 million and $30 million, with non-GAAP net loss per diluted share between $(0.09) and $(0.05). Continued strength in orders for package-level burn-in systems serving custom AI processors remains a central theme.

Management reiterated expectations for full-year fiscal 2026 revenue to finish on the high end of the $45 million to $50 million range. Key areas to monitor include follow-on production orders from the lead hyperscale customer, progress on silicon carbide customer expansions, and any updates to fiscal 2027 guidance during future earnings calls.

Broader industry dynamics, such as capital spending trends among semiconductor manufacturers and hyperscale data center operators, will also influence Aehr’s trajectory. Margin performance and the timing of large system deliveries are additional factors that could affect quarterly results.

Enhancing Research with Tickeron’s AI Tools

One thing that stands out when reviewing results like these is how much faster pattern and signal analysis becomes with the right tools. I often turn to Tickeron’s AI Screener to filter stocks by industry, technical indicators, and performance metrics. It helps surface comparable names or spot broader trends without manually combing through dozens of charts. In my view, incorporating an AI-driven screener into the workflow adds efficiency when evaluating companies exposed to AI infrastructure spending, though it remains just one part of a broader review process.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: AEHR

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


AEHR in upward trend: price rose above 50-day moving average on August 03, 2026

AEHR moved above its 50-day moving average on August 03, 2026 date and that indicates a change from a downward trend to an upward trend. In of 36 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AEHR's RSI Indicator exited the oversold zone, of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on August 03, 2026. You may want to consider a long position or call options on AEHR as a result. In of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for AEHR just turned positive on August 03, 2026. Looking at past instances where AEHR's MACD turned positive, the stock continued to rise in of 37 cases over the following month. The odds of a continued upward trend are .

Following a +3 3-day Advance, the price is estimated to grow further. Considering data from situations where AEHR advanced for three days, in of 278 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 262 cases where AEHR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

The 10-day moving average for AEHR crossed bearishly below the 50-day moving average on July 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AEHR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

AEHR broke above its upper Bollinger Band on August 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 64, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AEHR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (14.815) is normal, around the industry mean (8.253). P/E Ratio (19.449) is within average values for comparable stocks, (173.765). AEHR's Projected Growth (PEG Ratio) (0.000) is very low in comparison to the industry average of (1.534). AEHR has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.006). P/S Ratio (60.976) is also within normal values, averaging (35.325).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Applied Materials (NASDAQ:AMAT), Lam Research Corp (NASDAQ:LRCX), KLA Corporation (NASDAQ:KLAC), Teradyne (NASDAQ:TER), Ambarella (NASDAQ:AMBA).

Industry description

The electronic production equipment industry makes equipment used to produce semiconductors. Such equipment includes wafer fabrication, plasma etching and photo-resist processing equipment. The industry also makes chemical vapor deposition processing systems and photomasks, which are high-purity quartz plates that contain patterns to define integrated circuits layouts. Applied Materials, Inc., Lam Research Corporation, and KLA-Tencor Corporation are examples of electronic production equipment manufacturing companies.

Market Cap

The average market capitalization across the Electronic Production Equipment Industry is 64.45B. The market cap for tickers in the group ranges from 555.66K to 663.18B. ASML holds the highest valuation in this group at 663.18B. The lowest valued company is AVSR at 555.66K.

High and low price notable news

The average weekly price growth across all stocks in the Electronic Production Equipment Industry was 8%. For the same Industry, the average monthly price growth was -1%, and the average quarterly price growth was 46%. AXTI experienced the highest price growth at 60%, while SMTK experienced the biggest fall at -26%.

Volume

The average weekly volume growth across all stocks in the Electronic Production Equipment Industry was -47%. For the same stocks of the Industry, the average monthly volume growth was -41% and the average quarterly volume growth was -68%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 64
P/E Growth Rating: 34
Price Growth Rating: 43
SMR Rating: 74
Profit Risk Rating: 64
Seasonality Score: -23 (-100 ... +100)
View a ticker or compare two or three
AEHR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a manufacturer of burn-in and test equipment for semiconductor manufacturing

Industry ElectronicProductionEquipment

Profile
Details
Industry
Electronic Production Equipment
Address
400 Kato Terrace
Phone
+1 510 623-9400
Employees
136
Web
https://www.aehr.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Aehr Test Systems (AEHR) Delivers Record Bookings and Returns to GAAP Profitability in Fiscal 2026 Q4